Clinical Trial Update: Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial update for IBI-10090 in patients undergoing cataract surgery focusing on inflammatory reactions; study terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Reaction Due to Ocular Lens Prosthesis

Drugs mentioned

• IBI-10090 (IBI-10090)

Snippet

Sponsor: ICON Bioscience Inc | Conditions: Inflammatory Reaction Due to Ocular Lens Prosthesis | Phase 2 | Status: TERMINATED | Results posted: 2012-08-16